% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • biotuesday biotuesday Oct 29, 2013 11:47 PM Flag

    BioTuesdays: NeoStem completing enrolment in heart trial

    NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data readout six-to-eight months later.

    “AMR-001 represents the first compound in a class of cell therapies to have a highly defined cell population and an identified biologically effective therapeutic dose, both of which tie back to the biological mechanism of action that the outcomes of the current study are intended to demonstrate,” chairman and CEO Dr. Robin Smith says in an interview with BioTuesdays.

    Dr. Smith explains that NeoStem’s AMR-001 drug candidate brings a natural repair system, consisting of enriched CD34+ cells, to the heart in order to preserve heart function following a stent placement in patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI).

    ….see BIoTuesdays for rest of article….

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.250.00(0.00%)Jun 5 3:59 PMEDT